Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | PRKX | P51817 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308581 | 0.84 | MAPK7 (0.45) | MAPK1CCNCCDK8KMT2AMEN1 | |
| SCHEMBL949150 | 0.77 | CCNC (0.41) | LMNACCNCCDK8GCGRMAPK14 | |
| SCHEMBL6308496 | 0.76 | KMT2A (0.43) | KMT2AROCK2ROCK1MAPK14GRM1 | |
| SCHEMBL15758825 | 0.75 | CA12 (0.45) | — | |
| SCHEMBL6302445 | 0.72 | BRAF (0.53) | MAPK1LMNAKMT2ANT5EL3MBTL1 | |
| SCHEMBL5256520 | 0.72 | GCGR (0.49) | GCGRMAPK14 | |
| SCHEMBL6078860 | 0.72 | GCGR (0.49) | GCGRMAPK14 | |
| SCHEMBL1156055 | 0.72 | LMNA (0.63) | MAPK1LMNAKMT2ANT5EL3MBTL1 | |
| SCHEMBL949442 | 0.70 | IMPDH2 (0.56) | POLBROCK2PKN2CLK4GCGR | |
| SCHEMBL6310319 | 0.69 | CYP19A1 (0.41) | CCNCCDK8GCGRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | claimed |
| EP-1019394-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-07-19 | — | — | EP | claimed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | claimed |
| WO-1998052941-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| US-6852740-B2 | Pyrazole derivatives as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | PHARMACIA CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6503930-B1 | Treating cytokine-mediated diseases, such as inflammation | G.D. SEARLE & COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1019394-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6087381-A | AN ENZYME INHIBITOR FOR INHIBITING PHOSPHORYLATION MEDIATE THE PRODUCTION OF INFLAMMATORY CYTOKINES, TUMOR NECROSIS FACTOR; TREATING INFLAMMATION, ARTHRITIS, A TNF MEDICATED DISORDER | G. D. SEARLE & COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1998052941-A1 | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144529-A1 | Pyrazole derivatives as p38 kinase inhibitors | MAPK1, MAPK3, MAP3K1 | MAPK1 1/4885LMNA 4004/4885CCNC 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.